All Actio Biosciences articles
-
NewsJazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal
Jazz Pharmaceuticals has entered into a definitive agreement to acquire privately held Actio Biosciences for $820 million upfront, with up to a further $500 million available in contingent approval and sales milestones.